Earlier this year, Thrombopoietin Receptor Agonists, including NPlate and Revolade, became easier to access for ITP patients with the restrictions being removed. This was a big win for ITP Patients in Australia, which has improved the Quality of Life for many since this change.
Well, the changes don’t stop there!
We’re happy to announce that another TPORA, DOPTELET® from Swedish Orphan Biovitrum (Sobi) Pty Ltd, was listed on the Pharmaceutical Benefits Scheme (PBS) for treatment of severe thrombocytopenia in patients with chronic immune thrombocytopenia (ITP) who are refractory to other treatment.
Danielle Boyle, CEO and Founder of ITP Australia, and ITP Patient said
“ITP Australia has advocated for ITP patients to bring new and emerging technologies to Australia.”
“Whether through clinical trials or working with pharmaceutical companies like Sobi, the winner is ultimately Australians living with this rare and incurable disease.” she continued.
“Having access to this non-invasive treatment is a big win for ITP patients, as Doptelet improves platelet count and has limited side-effects.
“For ITP patients to have another treatment option available will reduce anxiety and offer an additional string to their treatment bow, as not every treatment works for every patient.”
Dr Phil Choi, lead author of the ITP Australia New Zealand Treatment Guidelines, Consultant Haematologist at Canberra Hospital and ITP Australia Medical Advisor said
“The PBS listing for DOPTELET® is the latest in a series of important advancements in the management of ITP in Australia. Recent changes to the restrictions on ITP therapies under the PBS have been a major step forward for doctors who treat ITP.
The addition of DOPTELET® to the PBS specifically broadens the choice now available to match the best treatment for the individual patient. I am excited that we can now provide our patients with a range of effective options without the need for splenectomy.
“DOPTELET® is an orally administered thrombopoietin receptor agonist (TPO-RA), a class of treatment we increasingly view as a mainstay of ITP management. In clinical trials, DOPTELET® has been shown to be safe and effective in the treatment for ITP, and the absence of food-related restrictions and liver safety testing make this a valuable therapy option for many Australians living with ITP”.
This article is for general information only and ITP Australia recommends that you speak with the treating clinician and/or healthcare professional about individual treatment decisions.
For more general information relating to Doptelet and other ITP treatments, visit ITPAustralia.org.au/treatments/
For information about the AUS/NZ Treatment Guidelines, visit ITPAustralia.org.au//thanz-aus-nz-itp-guidelines/